β-arrestin-1 deficiency protects mice from experimental colitis

American Journal of Pathology

Volumn 182, Issue 4, 2013, Pages 1114-1123

  Lee, Taehyung ^a   Lee, Eunhee ^a   Irwin, Regina ^a,b   Lucas, Peter C ^c   McCabe, Laura R ^a,b   Parameswaran, Narayanan ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Michigan State University   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 22; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; COLITIS; COLON; DEXTRAN SULFATE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MICE; MICE, KNOCKOUT; NF-KAPPA B; SIGNAL TRANSDUCTION; TRINITROBENZENESULFONIC ACID; WEIGHT LOSS;

EID: 84875128752     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.12.025     Document Type: Article

References (57)

1. P. Patwari, and R.T. Lee An expanded family of arrestins regulate metabolism Trends Endocrinol Metab 23 2012 216 222
2. E.J. Whalen, S. Rajagopal, and R.J. Lefkowitz Therapeutic potential of beta-arrestin- and G protein-biased agonists Trends Mol Med 17 2011 126 139
3. M. Zhang, X. Liu, Y. Zhang, and J. Zhao Loss of [beta]arrestin1 and [beta]arrestin2 contributes to pulmonary hypoplasia and neonatal lethality in mice Dev Biol 339 2010 407 417
4. E. Bezard, C.E. Gross, L. Qin, V.V. Gurevich, J.L. Benovic, and E.V. Gurevich L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain Neurobiol Dis 18 2005 323 335
5. H. Ohguro, S. Chiba, Y. Igarashi, H. Matsumoto, T. Akino, and K. Palczewski Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients Proc Natl Acad Sci USA 90 1993 3241 3245
6. J. Kim, L. Zhang, K. Peppel, J.H. Wu, D.A. Zidar, L. Brian, S.M. DeWire, S.T. Exum, R.J. Lefkowitz, and N.J. Freedman Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration Circ Res 103 2008 70 79
7. P. Li, J.A. Cook, G.S. Gilkeson, L.M. Luttrell, L. Wang, K.T. Borg, P.V. Halushka, and H. Fan Increased expression of beta-arrestin 1 and 2 in murine models of rheumatoid arthritis: isoform specific regulation of inflammation Mol Immunol 49 2011 64 74
8. J.K. Walker, A.M. Fong, B.L. Lawson, J.D. Savov, D.D. Patel, D.A. Schwartz, and R.J. Lefkowitz Beta-arrestin-2 regulates the development of allergic asthma J Clin Invest 112 2003 566 574
9. K.J. Porter, B. Gonipeta, S. Parvataneni, D.M. Appledorn, S. Patial, D. Sharma, V. Gangur, A. Amalfitano, and N. Parameswaran Regulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestins J Cell Physiol 225 2010 406 416
10. S.S. Seregin, D.M. Appledorn, S. Patial, M. Bujold, W. Nance, S. Godbehere, N. Parameswaran, and A. Amalfitano beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2 Virus Res 147 2010 123 134
11. H. Fan, A. Bitto, B. Zingarelli, L.M. Luttrell, K. Borg, P.V. Halushka, and J.A. Cook Beta-arrestin 2 negatively regulates sepsis-induced inflammation Immunology 130 2010 344 351
12. A.N. Ananthakrishnan, E.L. McGinley, K. Saeian, and D.G. Binion Trends in ambulatory and emergency room visits for inflammatory bowel diseases in the United States: 1994-2005 Am J Gastroenterol 105 2010 363 370
13. D.K. Podolsky Inflammatory bowel disease N Engl J Med 347 2002 417 429
14. C. Becker, H. Dornhoff, C. Neufert, M.C. Fantini, S. Wirtz, S. Huebner, A. Nikolaev, H.A. Lehr, A.J. Murphy, D.M. Valenzuela, G.D. Yancopoulos, P.R. Galle, M. Karow, and M.F. Neurath Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis J Immunol 177 2006 2760 2764
15. E. Cario Toll-like receptors in inflammatory bowel diseases: a decade later Inflamm Bowel Dis 16 2010 1583 1597
16. R.P. Gomariz, A. Arranz, C. Abad, M. Torroba, C. Martinez, F. Rosignoli, M. Garcia-Gómez, J. Leceta, and Y. Juarranz Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP J Leukoc Biol 78 2005 491 502
17. W. Strober, and I.J. Fuss Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases Gastroenterology 140 2011 1756 1767
18. S. Wirtz, C. Neufert, B. Weigmann, and M.F. Neurath Chemically induced mouse models of intestinal inflammation Nat Protoc 2 2007 541 546
19. L. Vereecke, M. Sze, C. Mc Guire, B. Rogiers, Y. Chu, M. Schmidt-Supprian, M. Pasparakis, R. Beyaert, and G. van Loo Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis J Exp Med 207 2010 1513 1523
20. S. Patial, S. Shahi, Y. Saini, T. Lee, N. Packiriswamy, D.M. Appledorn, J.J. Lapres, A. Amalfitano, and N. Parameswaran G-protein coupled receptor kinase 5 mediates lipopolysaccharide-induced NFkappaB activation in primary macrophages and modulates inflammation in vivo in mice J Cell Physiol 226 2011 1323 1333
21. S. Parvataneni, B. Gonipeta, N. Packiriswamy, T. Lee, H. Durairaj, and N. Parameswaran Role of myeloid-specific G-protein coupled receptor kinase-2 in sepsis Int J Clin Exp Med 4 2011 320 330
22. S. Patial, Y. Saini, S. Parvataneni, D.M. Appledorn, G.W. Dorn 2nd, J.J. Lapres, A. Amalfitano, P. Senagore, and N. Parameswaran Myeloid-specific GPCR kinase-2 negatively regulates NF-kappaB1p105-ERK pathway and limits endotoxemic shock in mice J Cell Physiol 226 2011 627 637
23. K.J. Motyl, S. Botolin, R. Irwin, D.M. Appledorn, T. Kadakia, A. Amalfitano, R.C. Schwartz, and L.R. McCabe Bone inflammation and altered gene expression with type I diabetes early onset J Cell Physiol 218 2009 575 583
24. A. Araki, T. Kanai, T. Ishikura, S. Makita, K. Uraushihara, R. Iiyama, T. Totsuka, K. Takeda, S. Akira, and M. Watanabe MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis J Gastroenterol 40 2005 16 23
25. L.A. Dieleman, M.J. Palmen, H. Akol, E. Bloemena, A.S. Peña, S.G. Meuwissen, and E.P. Van Rees Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines Clin Exp Immunol 114 1998 385 391
26. L.A. Dieleman, B.U. Ridwan, G.S. Tennyson, K.W. Beagley, R.P. Bucy, and C.O. Elson Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice Gastroenterology 107 1994 1643 1652
27. A.A. te Velde, M.I. Verstege, and D.W. Hommes Critical appraisal of the current practice in murine TNBS-induced colitis Inflamm Bowel Dis 12 2006 995 999
28. R. Kühn, J. Löhler, D. Rennick, K. Rajewsky, and W. Müller Interleukin-10-deficient mice develop chronic enterocolitis Cell 75 1993 263 274
29. J. Lindsay, C. Van Montfrans, F. Brennan, S. Van Deventer, P. Drillenburg, H. Hodgson, A. Te Velde, and M. Sol Rodriguez Pena IL-10 gene therapy prevents TNBS-induced colitis Gene Ther 9 2002 1715 1721
30. J.H. Cox, N.M. Kljavin, N. Ota, J. Leonard, M. Roose-Girma, L. Diehl, W. Ouyang, and N. Ghilardi Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice Mucosal Immunol 5 2012 99 109
31. K. Sugimoto, A. Ogawa, E. Mizoguchi, Y. Shimomura, A. Andoh, A.K. Bhan, R.S. Blumberg, R.J. Xavier, and A. Mizoguchi IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis J Clin Invest 118 2008 534 544
32. G. Pickert, C. Neufert, M. Leppkes, Y. Zheng, N. Wittkopf, M. Warntjen, H.A. Lehr, S. Hirth, B. Weigmann, S. Wirtz, W. Ouyang, M.F. Neurath, and C. Becker STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing J Exp Med 206 2009 1465 1472
33. J. Mudter, and M.F. Neurath IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance Inflamm Bowel Dis 13 2007 1016 1023
34. Y. Umehara, M. Kudo, R. Nakaoka, T. Kawasaki, and M. Shiomi Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis Hepatogastroenterology 53 2006 879 882
35. I. Atreya, R. Atreya, and M.F. Neurath NF-kappaB in inflammatory bowel disease J Intern Med 263 2008 591 596
36. O.J. Broom, B. Widjaya, J. Troelsen, J. Olsen, and O.H. Nielsen Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 158 2009 272 280
37. S. Nell, S. Suerbaum, and C. Josenhans The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models Nat Rev Microbiol 8 2010 564 577
38. T. Hibi, H. Ogata, and A. Sakuraba Animal models of inflammatory bowel disease J Gastroenterol 37 2002 409 417
39. D. Seegert, P. Rosenstiel, H. Pfahler, P. Pfefferkorn, S. Nikolaus, and S. Schreiber Increased expression of IL-16 in inflammatory bowel disease Gut 48 2001 326 332
40. N. Nishimoto, and T. Kishimoto Interleukin 6: from bench to bedside [Erratum appeared in Nat Clin Pract Rheumatol 2006, 2:691] Nat Clin Pract Rheumatol 2 2006 619 626 and 691
41. J. Mudter, L. Amoussina, M. Schenk, J. Yu, A. Brüstle, B. Weigmann, R. Atreya, S. Wirtz, C. Becker, A. Hoffman, I. Atreya, S. Biesterfeld, P.R. Galle, H.A. Lehr, S. Rose-John, C. Mueller, M. Lohoff, and M.F. Neurath The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6 J Clin Invest 118 2008 2415 2426
42. J. Mudter, J. Yu, L. Amoussina, B. Weigmann, A. Hoffman, K. Rücknagel, P.R. Galle, and M.F. Neurath IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation Arch Immunol Ther Exp (Warsz) 57 2009 369 376
43. J. Gay, E. Kokkotou, M. O'Brien, C. Pothoulakis, and K.P. Karalis Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines Neuroimmunomodulation 13 2006 114 121
44. K. Mitsuyama, M. Sata, and K. Tanikawa Significance of interleukin-6 in patients with inflammatory bowel disease Gastroenterol Jpn 26 1991 20 28
45. Y. Murata, Y. Ishiguro, J. Itoh, A. Munakata, and Y. Yoshida The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis J Gastroenterol 30 Suppl 8 1995 56 60
46. T. Hosokawa, K. Kusugami, K. Ina, T. Ando, M. Shinoda, A. Imada, M. Ohsuga, T. Sakai, T. Matsuura, K. Ito, and K. Kaneshiro Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease J Gastroenterol Hepatol 14 1999 987 996
47. A.K. Lovgren, J.J. Kovacs, T. Xie, E.N. Potts, Y. Li, W.M. Foster, J. Liang, E.B. Meltzer, D. Jiang, R.J. Lefkowitz, and P.W. Noble Beta-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix Sci Transl Med 3 2011 74ra23
48. S. Tsutsui, D. Vergote, N. Shariat, K. Warren, S.S. Ferguson, and C. Power Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and beta-arrestin-1 in monocytoid cells FASEB J 22 2008 786 796
49. N. Parameswaran, C.S. Pao, K.S. Leonhard, D.S. Kang, M. Kratz, S.C. Ley, and J.L. Benovic Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages J Biol Chem 281 2006 34159 34170
50. Y. Wang, Y. Tang, L. Teng, Y. Wu, X. Zhao, and G. Pei Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling Nat Immunol 7 2006 139 147
51. C.T. Weaver, R.D. Hatton, P.R. Mangan, and L.E. Harrington IL-17 family cytokines and the expanding diversity of effector T cell lineages Annu Rev Immunol 25 2007 821 852
52. P. Ye, F.H. Rodriguez, S. Kanaly, K.L. Stocking, J. Schurr, P. Schwarzenberger, P. Oliver, W. Huang, P. Zhang, J. Zhang, J.E. Shellito, G.J. Bagby, S. Nelson, K. Charrier, J.J. Peschon, and J.K. Kolls Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense J Exp Med 194 2001 519 527
53. M. Raffatellu, R.L. Santos, D.E. Verhoeven, M.D. George, R.P. Wilson, S.E. Winter, I. Godinez, S. Sankaran, T.A. Paixao, M.A. Gordon, J.K. Kolls, S. Dandekar, and A.J. Bäumler Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut Nat Med 14 2008 421 428
54. H. Park, Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, Y.H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nat Immunol 6 2005 1133 1141
55. K. Hirota, M. Hashimoto, H. Yoshitomi, S. Tanaka, T. Nomura, T. Yamaguchi, Y. Iwakura, N. Sakaguchi, and S. Sakaguchi T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis J Exp Med 204 2007 41 47
56. Y. Zheng, D.M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis Nature 445 2007 648 651
57. S. Fujino, A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama Increased expression of interleukin 17 in inflammatory bowel disease Gut 52 2003 65 70